NYT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
New York Times Co (NYT) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive news catalysts, and favorable analyst ratings support this decision. Additionally, the SwingMax signal indicates a recent entry opportunity, which aligns with the investor's goals.
The technical indicators are mixed but lean slightly positive. The RSI is neutral at 62.53, MACD is below 0 but negatively contracting, and moving averages are converging. The stock is trading near its resistance level (R1: 73.669), suggesting potential for upward movement if it breaks through. However, the stock's historical trend suggests a 40% chance of a slight decline (-0.92%) in the next day, but a modest 0.32% gain in the next week.
The introduction of the 'Family Plan' has driven 450,000 new digital subscribers in Q4, raising total subscribers to 12.8 million and pushing digital revenues past $2 billion for the first time.
Strong financial performance in Q4 2025, with revenue up 10.42% YoY, net income up 4.94% YoY, and EPS up 6.76% YoY.
Positive sentiment from analysts, with multiple price target increases post-Q4 results.
The MACD histogram is below 0, indicating potential bearish momentum.
The stock's historical trend suggests a 40% chance of a slight decline in the next day and a potential -3.7% drop in the next month.
Higher expense outlook noted by JPMorgan analyst, which could pressure margins.
In Q4 2025, the company showed strong growth trends: Revenue increased by 10.42% YoY to $802.31 million, net income rose by 4.94% YoY to $129.84 million, EPS increased by 6.76% YoY to 0.79, and gross margin improved to 51.63%, up 2.08% YoY. This demonstrates solid operational performance and growth momentum.
Analysts are generally positive on NYT. Recent updates include Citi lowering its price target to $77 (from $81) while maintaining a Buy rating, JPMorgan raising its target to $74 (from $71) with an Overweight rating, and Evercore ISI increasing its target to $75 (from $69) with an Outperform rating. Guggenheim and Barclays remain more cautious with Neutral and Equal Weight ratings, respectively, but have also raised their price targets.
